OPKO Health, Inc.
NASDAQ:OPK · NASDAQ Global Select
+$0.01 today
Vol 4.82M · Avg 2.59M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:OPK · Revenue to Net Income
Key Ratios
Analysis
$581.1M of revenue converted into -$212.9M of net income for the selected period. Gross margin is 22.7% and net margin is -36.4%, showing how much revenue survives after costs and taxes. EPS is $-0.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $606.9M -14.9% | $713.1M -17.4% | $863.5M -14.0% | $1.0B -43.4% | $1.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $478.8M +19.1% | $402.1M -26.3% | $545.4M -23.8% | $716.0M -40.0% | $1.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $128.1M -58.8% | $311.0M -2.2% | $318.1M +10.4% | $288.2M -50.4% | $581.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 21.1% -22.5pp | 43.6% +6.8pp | 36.8% +8.1pp | 28.7% -4.1pp | 32.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $124.0M +17.9% | $105.2M +17.4% | $89.6M +21.3% | $73.9M -3.9% | $76.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $223.0M -26.7% | $304.2M +1.2% | $300.6M -19.4% | $372.7M -20.5% | $468.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $347.0M -25.1% | $463.1M -2.5% | $475.1M -7.6% | $514.5M -8.6% | $562.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $91.6M -6.7% | $98.2M -6.8% | $105.3M -3.1% | $108.7M +38.0% | $78.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.3M -130.5% | $135.3M +306.5% | -$65.5M +75.8% | -$270.8M -424.0% | $83.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -6.8% -25.8pp | 19.0% +26.6pp | -7.6% +19.4pp | -27.0% -31.7pp | 4.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$219.0M -44.0% | -$152.1M +3.2% | -$157.0M +30.6% | -$226.3M -1306.7% | $18.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -36.1% -14.8pp | -21.3% -3.1pp | -18.2% +4.3pp | -22.5% -23.6pp | 1.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $14.8M +75.8% | $8.4M +111.5% | $4.0M +101.1% | $2.0M +6975.0% | $28.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $108.5M +128.5% | $47.5M +251.4% | $13.5M +12.0% | $12.1M -36.1% | $18.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$22.4M -115.8% | $141.7M +617.1% | -$27.4M +83.5% | -$165.7M -395.9% | -$33.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$241.4M -2229.6% | -$10.4M +94.4% | -$184.4M +52.9% | -$391.9M -2574.4% | -$14.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -39.8% -38.3pp | -1.5% +19.9pp | -21.4% +17.7pp | -39.0% -38.2pp | -0.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$15.7M -136.7% | $42.8M +865.6% | $4.4M +107.0% | -$63.5M -510.0% | $15.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$225.7M -324.0% | -$53.2M +71.8% | -$188.9M +42.5% | -$328.4M -989.5% | -$30.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -37.2% -29.7pp | -7.5% +14.4pp | -21.9% +10.8pp | -32.7% -31.0pp | -1.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -291.1% | -$0 +69.3% | -$0 +45.7% | -$0 -911.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -291.1% | -$0 +69.3% | -$0 +45.7% | -$0 -911.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $751.1M +8.2% | $694.0M -7.7% | $751.8M +4.5% | $719.1M +11.0% | $648.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $751.1M +8.2% | $694.0M -7.7% | $751.8M +4.5% | $719.1M +11.0% | $648.1M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.36B
Nektar Therapeutics
NASDAQ:NKTR
$1.17B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.07B
Xencor, Inc.
NASDAQ:XNCR
$934.93M
Personalis, Inc.
NASDAQ:PSNL
$900.48M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$883.85M
Sana Biotechnology, Inc.
NASDAQ:SANA
$852.99M
Oculis Holding AG
NASDAQ:OCS
$628.86M
Claritev Corporation
NYSE:CTEV
$504.61M
LifeMD, Inc.
NASDAQ:LFMD
$229.24M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does OPK generate?
OPKO Health, Inc. (OPK) reported $606.88M of revenue in fiscal 2025.
Is OPK profitable?
OPKO Health, Inc. (OPK) reported -$225,680,000.00 of net income, with a net margin of -37.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.